Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies by unknown
Liu et al. Lipids in Health and Disease 2013, 12:159
http://www.lipidworld.com/content/12/1/159REVIEW Open AccessEffects of blood triglycerides on cardiovascular
and all-cause mortality: a systematic review and
meta-analysis of 61 prospective studies
Jun Liu1†, Fang-Fang Zeng1†, Zhao-Min Liu2, Cai-Xia Zhang1, Wen-hua Ling1 and Yu-Ming Chen1*Abstract
The relationship of triglycerides (TG) to the risk of death remains uncertain. The aim of this study was to determine
the associations between blood triglyceride levels and cardiovascular diseases (CVDs) mortality and all-cause
mortality. Four databases were searched without language restriction for relevant studies: PubMed, ScienceDirect,
EMBASE, and Google Scholar. All prospective cohort studies reporting an association between TG and CVDs or
all-cause mortality published before July 2013 were included. Risk ratios (RRs) with 95% confidence intervals (CIs)
were extracted and pooled according to TG categories, unit TG, and logarithm of TG using a random-effects model
with inverse-variance weighting. We identified 61 eligible studies, containing 17,018 CVDs deaths in 726,030
participants and 58,419 all-cause deaths in 330,566 participants. Twelve and fourteen studies, respectively, reported
the effects estimates of CVDs and total mortality by TG categories. Compared to the referent (90–149 mg/dL), the
pooled RRs (95% CI) of CVDs mortality for the lowest (< 90 mg/dL), borderline-high (150–199 mg/dL), and high TG
(≥ 200 mg/dL) groups were 0.83 (0.75 to 0.93), 1.15 (1.03 to 1.29), and 1.25 (1.05 to 1.50); for total mortality they
were 0.94 (0.85 to 1.03), 1.09 (1.02 to 1.17), and 1.20 (1.04 to 1.38), respectively. The risks of CVDs and all-cause
deaths were increased by 13% and 12% (p < 0.001) per 1-mmol/L TG increment in twenty-two and twenty-two
studies reported RRs per unit TG, respectively. In conclusion, elevated blood TG levels were dose-dependently
associated with higher risks of CVDs and all-cause mortality.
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There is considerable evidence to suggest that triglycer-
ides (TG) play a role in such adverse health conditions
as heart disease, peripheral vascular disease, stroke, dia-
betes mellitus, metabolic syndrome, and cancer, which
are common causes of death [1-3]. Several reviews and
meta-analyses evaluated the association between blood
TG and mortality. Hokanson et al. reported the sum-
mary crude RR for and CVDs death in the sensitive ana-
lysis of a meta-analysis assessing the association of TG
with CVDs incidence [4], in which seventeen prospective
studies of American and European participants were in-
cluded. Two meta-analyses by Hokanson et al. updated* Correspondence: chenyum@mail.sysu.edu.cn
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reproduction in any medium, provided the orthe overall effect of TG on CVDs incidence but not for
CVDs mortality [5,6]. The collaboration studies from the
Asia Pacific Cohort Studies Collaboration (APCSC) sug-
gested that elevated TG levels were strongly associated with
an increased mortality of coronary heart disease (CHD)
[7,8]. Another collaborative analysis including 10,269 par-
ticipants from 7 studies in Europe, reported that higher tri-
glyceride (≥ 1.7 versus. < 1.7 mmol/L) was associated with
an increased risk of CVDs (but not all-cause) moratity in
women and men [9]. Up to date, no study has assessed the
overall effects of TG on CVDs death or all-cause death by
including all eligible studies in the world. We conducted a
systematic review and meta-analysis of prospective studies
to evaluate the association between blood TG levels and
CVDs mortality and all-cause mortality.This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Literature search strategies
Following the methodology advocated in the Meta-Analysis
of Observational Studies in Epidemiology (MOOSE) guide-
lines [10] and without language restrictions, we carried out
a systematic search of four electronic databases, PubMed
(1966 to July 2013), ScienceDirect (1960 to July 2013),
EMBASE (1980 to July 2013), and Google Scholar (http://
scholar.google.com) without language restrictions using the
following search terms: (i) triglyceride* or triacylglycerol* or
TG or lipids; (ii) blood or serum or plasma or circulating;
(iii) cohort* or longitudinal or follow-up or prospective or
relative risk* or hazard ratio*; (iv) death* or mortali*; and
(v) (i) AND (ii) AND (iii) AND (iv). We also searched the
reference lists of original and review articles to identify
more studies. Related studies generated by PubMed were
also retrieved. If necessary, we contacted authors for add-
itional data.
Inclusion and exclusion criteria
We included studies that met all of the following criteria:
(1) prospective cohort design in a general population; (2)
the exposure of interest included TG; (3) the outcome of
interest included all-cause mortality or CVDs mortality;
and (4) the relative risks (RRs) or hazard ratios (HRs) with
their corresponding 95% confidence intervals (CIs) (or suf-
ficient data to estimate them) were reported according to
at least three TG categories, or by unit of TG, or by loga-
rithmically transformed TG. We excluded studies that
were focused on patients with one or several specific types
of disease, such as diabetes, CVDs, dyslipidemia, or can-
cer. If multiple published reports from the same popula-
tion resource or overlapping datasets were available, we
included only the most relevant article with the largest
dataset.
Data extraction and quality assessment
Two epidemiologists (JL and FFZ) independently assessed
the eligible studies, collected information, and assessed the
quality of the data. Any discrepancies were resolved
through discussion. All relevant information was recorded,
included the article title, the first author’s name, publica-
tion year, country in which the study was performed, popu-
lation inclusion and exclusion criteria, sample size at
baseline, mean (range) duration of follow-up, mean (range)
age at baseline, proportion of men, geographic location,
type of blood sample (serum, plasma, or other), fasting sta-
tus (yes, no, or other), whether there was an adjustment
for total cholesterol (TC) or not, and risk estimate (RR or
HR) with corresponding 95% CI after controlling for both
the minimally and the maximally adjusted number of
covariates.
The Newcastle-Ottawa Quality Assessment Scale
(NOS) was applied to assess the quality of each includedstudy [11]. The NOS was designed to assesses the quality
of cohort studies in terms of their selection of participants
(four criteria), degree of comparability between study
groups (one criterion), and assessment of outcomes (three
criteria). Total scores range from 1 to 9, with 9 being the
maximum.
Statistical analysis
We conducted three separate meta-analyses for the risk
estimates on the basis of the TG categories, unit TG, and
logarithm of TG. For the category data, we standardized
and grouped the TG levels with unit mg/dL into the four
categories used in the Adult Treatment Panel III (ATP III)
cholesterol guidelines [12]: lowest group (< 90 mg/dL),
intermediate group (90–149 mg/dL), borderline hypertri-
glyceridemia group (150–199 mg/dL), and hypertriglyc-
eridemia group (≥ 200 mg/dL). The intermediate group
was used as the referent. As the highest category in each
individual study was open-ended, we assigned the category
a value equal to 50% of the width of its lower boundary. If
one or more group in a single study fell into the same cat-
egory, we pooled these risk estimates first. We analyzed
the dose–response relationships using the method pro-
posed by Greenland et al. [13,14]. Study-specific slopes
(linear trends) were calculated from the natural log of the
RRs across various exposure levels, correlated with their
corresponding TG levels. The original dose groups were
used in the dose–response relationship analysis. For the
studies reporting the risk estimates by unit TG, the RRs
were standardized to a 1-mmol/L increase in TG accord-
ing to the following formulas.
RRst ¼ exp lnRRo=kð Þ;
95% CI ¼ exp lnRRo=k  1:96SEo=kð Þ
SEo ¼ lnRRo ul–lnRRo llð Þ= 2  1:92ð Þ
Where, RRst is the standardized RR; RRo is derived
from the confidence intervals provided in each study; ul is
the upper limit; ll is the lower limit; and k refers to the per
k-mmol/L increase in TG levels in the original study.
For the studies reporting the risk estimates by loga-
rithmically transformed TG, we pooled the risk esti-
mates per unit of log of TG (mmol/L).
The DerSimonian and Laird random-effects model of
inverse variance methods was used to estimate the pooled
risks and 95% CIs [15]. RRs were used for all of the risk es-
timates including RRs and HRs. Unless otherwise stated,
we used the most fully adjusted RRs from each study. Stat-
istical heterogeneity was tested with the I2 statistic; I2
values of 25% to < 50%, 50% to < 75%, and ≥ 75% were
considered to represent small, medium, and large degree
of inconsistency, respectively [16]. The Begg’s and Egger’s
regression tests were used to detect any publication bias
Figure 1 Flow diagram of study selection. TG: Triglycerides; CVDs:
Cardiovascular diseases.
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any suspected publication bias once identified [19].
Subgroup analyses were carried out to identify possible
sources of heterogeneity and to check for the potential
effects of age (≥ 50 or not), gender (men/women),Figure 2 Pooled estimate of RR with 95% CI of all-cause mortality for
horizontal lines indicate the 95% confidence interval (CI). Triglycerides (TG)
referent), borderline high (150–199 mg/dL), and high (≥ 200 mg/dL).duration of follow-up (≥15 or not), sample size (≥ 4000
or not), fasting status (Yes or No), geographic location
(Europe/America or Asia-Pacific), blood sample (serum/
plasma), free CVDs history at baseline (Yes or No),
study quality (> 6 score or not), and adjustment for TC
(Yes or No) on the relationship between TG and the
outcomes. We also performed a meta-regression to ex-
plore the independent influences of these factors on het-
erogeneity and then sensitivity analysis on the main
effects by excluding all of the studies one by one to
evaluate whether any single or group of studies might
markedly affect the results. We also compared the
pooled estimates using RRs adjusted for the minimal
and maximal number of covariates in the studies that re-
ported both. Finally, using the methods proposed by
Mantel and Haenszel, we performed the chi-square test
for heterogeneity to examine differences in pooled RRs
[20]. All of these tests were two-sided and statistical sig-
nificance was defined as P < 0.05. The analyses were per-
formed with the Stata statistical software version 11.0
(College Station, TX, USA).Results
Study characteristics
Figure 1 outlines our search and selection process, and
illustrates the detailed population selection criteria in
the original studies. A total of 61 studies included in the
present meta-analysis were pooled according to CVDs
mortality and all-cause mortality. They were allcategory analysis. Squares indicate the adjusted relative risk (RR) and
groups: lowest (<90 mg/dL), intermediate (90–149 mg/dL, the
Figure 3 Pooled estimate of RR with 95% CI of CVDs mortality for categorical analysis. Squares indicate the adjusted relative risk (RR) and
horizontal lines indicate the 95% confidence interval (CI). Triglycerides (TG) groups: lowest (<90 mg/dL), intermediate (90–149 mg/dL, the
referent), borderline high (150–199 mg/dL), and high (≥ 200 mg/dL). CVDs: cardiovascular diseases.
Figure 4 Pooled estimate of RR with 95% CI of CVDs and all-cause mortality for a 1-mmol/L increase of TG. Squares indicate the adjusted
relative risk (RR) and horizontal lines indicate the 95% confidence interval (CI). TG: Triglycerides; CVDs: cardiovascular diseases.
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Figure 5 Pooled estimate of RR and 95% CI of CVDs and all-cause mortality for a 1-ln (mmol/L) increase of TG. TG: Triglycerides; CVDs:
cardiovascular diseases; CI, confidence interval; RR, relative risk.
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in Norwegian study [21]. The features of these studies
are summarized in Additional file 1: Table S1. Thirty-
three studies reported data on CVDs mortality; together
recording 17,018 CVDs deaths in 726,030 participants;
and 38 studies reported data on all-cause mortality, to-
gether recording 58,419 deaths in 330,566 participants.Table 1 Pooled relative risks of CVDs and all-cause mortality
N Overall effects I2 P
hRR (95% CIs) † P (%)
Cardiovascular disease mortality
TG groups, mg/dl
<90 10 0.83 (0.75, 0.93) 0.001 21.6 0
90-150 12 1.00 (referent)
150-200 12 1.15 (1.03, 1.29) 0.015 22.5 0
>200 8 1.25 (1.05, 1.50) 0.013 66.2 0
Per 1 mmol/L TG 22 1.13 (1.07, 1.19) 0.000 65.9 0
Per 1ln (mmol/L TG) 9 1.16 (1.05, 1.29) 0.004 32.3 0
All-cause mortality
TG groups, mg/dl
<90 12 0.94 (0.85, 1.03) 0.150 71.1 0
90-150 14 1.00 (referent)
150-200 14 1.09 (1.02, 1.17) 0.011 33.3 0
00A0 > 200 8 1.20 (1.04, 1.38) 0.011 75.4 0
Per 1 mmol/L TG 22 1.12 (1.07, 1.16) 0.000 75.9 0
Per 1 ln (mmol/L TG) 8 1.11 (1.01, 1.23) 0.030 62.4 0
† Random-effects model.
RR, relative risk; CI, confidence interval; TG: triglycerides; CVDs: cardiovascular diseasThe median age at the recruitment was 48.0 and median
duration of follow-up was 12.0 years.
Overall effects of triglycerides on CVDs and
all-cause mortality
Twelve and fourteen studies, respectively, reported the ef-
fects estimates of CVDs and total mortality by TGby blood TG levels
for
eterogeneity
Begg’s test Influence analyses
(P value) Minimum Maximum
.244 0.592 0.80 (0.71, 0.91) 0.85 (0.76, 0.94)
.222 0.150 1.12 (1.00, 1.27) 1.19 (1.08, 1.32)
.004 0.711 1.22 (1.00, 1.49) 1.33 (1.13, 1.57)
.000 1.000 1.11 (1.06, 1.17) 1.14 (1.08, 1.20)
.160 0.754 1.06 (1.02,1.11) 1.24 (1.11, 1.39)
.000 0.732 0.90 (0.83, 0.97) 0.96 (0.84, 1.06)
.108 1.000 1.08 (1.00, 1.16) 1.11 (1.04, 1.19)
.000 0.711 1.17 (1.01, 1.35) 1.25 (1.14, 1.37)
.000 0.866 1.11 (1.07, 1.15) 1.13 (1.08, 1.18)
.010 0.711 1.08 (0.99, 1.18) 1.14 (1.02, 1.28)
es.
Table 2 Pooled relative risks of CVDs mortality for categorical and continuous analyses in subgroups
Sub-groups Triglyceride group (mg/dl) Per 1 mmol/L TG
<90 90-146 150-199 ≥200
N* RR (95% CI) N* RR† N* RR (95% CI) N* RR (95% CI) N* RR (95% CI)
Age (year)
<50 3 0.84 (0.74, 0.96) 4 1.00 4 1.21 (1.06, 1.40) 3 1.20 (0.94, 1.53) 10 1.11 (1.01, 1.22)
≥50 7 0.85 (0.68, 1.05) 8 1.00 8 1.08 (0.90, 1.30) 5 1.30 (0.99, 1.69) 12 1.15 (1.09, 1.22)
P value 0.956 0.338 0.664 0.488
Gender
Male 5 0.86 (0.67, 1.09) 5 1.00 5 1.06 (0.89, 1.30) 5 1.31 (1.12, 1.15) 18 1.10 (1.04, 1.15)
Female 3 0.76 (0.64, 0.90) 3 1.00 3 1.37 (1.09, 1.71) 2 2.08 (1.44, 3.00) 9 1.40 (1.22, 1.59)
Mixed 4 1.01 (0.65, 1.56) 6 1.00 6 1.14 (1.10, 1.31) 4 1.26 (0.99, 1.60) 4 1.16 (1.08, 1.25)
P value 0.416 0.100 0.023 0.001
Follow-up (year)
<12 6 0.81 (0.71, 0.91) 6 1.00 6 1.01 (0.84, 1.19) 4 1.25 (0.84, 1.84) 11 1.14 (1.06, 1.22)
≥12 4 0.79 (0.61, 1.02) 4 1.00 6 1.27 (1.13, 1.44) 4 1.25 (1.01, 1.54) 11 1.11 (1.02, 1.21)
P value 0.473 0.025 0.992 0.694
Fast status
Fast 6 0.89 (0.71, 1.12) 7 1.00 7 1.15 (0.98, 1.35) 4 1.42 (1.22, 1.64) 10 1.10 (1.04, 1.17)
Nonfast 3 1.00 (0.65, 1.54) 4 1.00 4 1.14 (0.85, 1.46) 4 1.11 (0.85, 1.46) 7 1.12 (1.01, 1.23)
Others§ 1 0.80 (0.69, 0.93) 1 1.00 1 1.15 (0.90, 1.45) 0 - 5 1.19 (1.00, 1.41)
P value 0.646 0.843 0.122 0.821
Geographic location
Europe/America 7 0.86 (0.73, 1.01) 8 1.00 8 1.17 (1.00, 1.37) 5 1.22 (1.02, 1.55) 18 1.11 (1.05, 1.17)
Asia-Pacific 3 0.80 (0.70, 0.92) 4 1.00 4 1.20 (0.93, 1.35) 3 1.20 (0.82, 1.77) 4 1.26 (1.05, 1.52)
P value 0.509 0.729 0.847 0.205
Quality score
<7 4 0.76 (0.65, 0.90) 5 1.00 5 1.01 (0.80, 1.29) 4 1.24 (0.91, 1.68) 8 1.16 (1.04, 1.29)
7-9 6 0.92 (0.77, 1.05) 7 1.00 7 1.23 (1.09, 1.38) 4 1.25 (0.98, 1.60) 14 1.11 (1.04, 1.19)
P value 0.100 0.167 0.961 0.509
Sample size
<4000 7 0.84 (0.70, 1.02) 7 1.00 7 1.10 (0.91, 1.32) 4 1.49 (1.21, 1.80) 10 1.14 (1.06, 1.22)
≥4000 3 0.83 (0.71, 0.97) 5 1.00 5 1.18 (1.02, 1.38) 4 1.12 (0.84, 1.45) 12 1.13 (1.04, 1.22)
P value 0.910 0.541 0.100 0.883
Free of CVDs at baseline
Yes 6 0.85 (0.76, 0.96) 7 1.00 7 1.12 (0.92, 1.36) 6 1.20 (0.96, 1.50) 13 1.11 (1.04, 1.20)
No 4 0.88 (0.67, 1.56) 5 1.00 5 1.16 (1.00, 1.34) 2 1.43 (1.16, 1.76) 9 1.16 (1.09, 1.24)
P value 0.832 0.811 0.265 0.371
Adjustment
Minimally 4 0.72 (0.55, 0.94) 5 1.00 5 1.44 (1.16, 1.78) 4 1.52 (1.14, 2.02) 7 1.15 (1.08, 1.22)
Maximally 4 0.87 (0.77, 0.98) 5 1.00 5 1.24 (1.05, 1.46) 4 1.29 (1.01, 1.65) 7 1.05 (0.99, 1.11)
P value 0.207 0.271 0.398 0.033
Adjustment for TC
Yes 4 0.85 (0.77, 0.94) 4 1.00 4 1.24 (1.07, 1.43) 3 1.27 (0.94, 1.71) 14 1.09 (1.03, 1.16)
No 6 0.82 (0.61, 1.09) 8 1.00 8 1.06 (0.89, 1.26) 5 1.25 (0.97, 1.61) 8 1.21 (1.10, 1.34)
P value 0.810 0.169 0.927 0.078
Liu et al. Lipids in Health and Disease 2013, 12:159 Page 6 of 11
http://www.lipidworld.com/content/12/1/159
Table 2 Pooled relative risks of CVDs mortality for categorical and continuous analyses in subgroups (Continued)
Adjustment for HDL
Yes 3 0.81 (0.72, 0.91) 3 1.00 3 1.23 (1.04, 1.47) 1 1.52 (1.14, 2.02) 3 1.10 (1.03, 1.19)
No 7 0.84 (0.68, 1.04) 9 1.00 9 1.09 (0.94, 1.27) 7 1.21 (1.00, 1.47) 19 1.13 (1.06, 1.20)
P value 0.734 0.313 0.200 0.679
*The number of cohorts.
†Reference group.
§Others included mixed and unknown ones.
RR, relative risk; CI, confidence interval; CVDs: cardiovascular diseases; HDL: high-density lipoprotein.
TG: triglycerides; TC: total cholesterol.
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(90 mg/dL-149 mg/dL), those with TG level less than
90 mg/dL had no significant risk of all-cause mortality, but
had less risk of CVDs moratlity, those with borderline
hypertriglyceridemia (150 mg/dl-199 mg/dl) hypertriglyc-
eridemia (≥ 200 mg/dL) had a greater risk of CVDs and
all-cause mortality (Figure 2 and Figure 3). The dose–
response analysis showed that the risk of CVDs and
total mortality was increased by 13% (8%-19%) and 10%
(6%-14%) per 1-mmol/L TG increment (Additional
file 2: Figure S2).
Twenty-two and twenty-two studies, respectively, were
included in the analysis of risk for CVDs and total mortal-
ity by unit TG, and nine and eight studies, respectively, re-
ported the results of CVDs and total mortality by log TG.
Figure 4 and Figure 5 show overall association of TG with
the risks of CVDs and all-cause mortality.
The heterogeneity across studies varied from null to
large (I2 = 0%–75.9%) and no obvious publication biases
were observed (P = 0.150 to 1.00) in the foregoing ana-
lyses (Table 1).
Sensitivity and subgroup analyses
The subgroup analyses showed that the pooled RRs were
significantly higher in men than in women and higher in
studies with longer follow-up durations for the risk of
both CVDs and total mortality; and tended to be higher
for CVDs mortality in the studies that adjusted for TC
(RR: 1.09 versus 1.21, P = 0.078). Similar results were ob-
served in the meta-regression analyses. No other signifi-
cant between-group heterogeneities were observed in
the subgroup analyses (Tables 2 and 3) or in the meta-
regression (Additional file 3: Table S3).
Sensitivity and influence analyses were conducted on
the pooled risks and the associations of the lowest group
tended to be vague when one studies [22] was excluded
for total mortality. No single study significantly influ-
enced the pooled estimates risks by unit of TG or for
any other of TG categories group. The pooled maximally
adjusted RR of CVDs mortality was markedly lower than
that of its minimally adjusted RR in the continuous ana-
lysis (RR =1.05 versus 1.15, P = 0.033), but not in the cat-
egorical analysis (P: 0.207 to 0.398). No significantdifferences were observed in the all-cause mortality data
(P: 0.222 to 0.487) (Tables 2 and 3).
Discussion
We quantitatively assessed the association between
blood triglyceride levels at baseline and CVDs mortality
in 33 studies with 17,018 cases among 726,030 partici-
pants, as well as all-cause mortality in 38 studies with
58,419 cases among 360,566 participants. Compared to
the referent, the risks of CVDs and all-cause mortality
were increased by 15.0% and 9.0% in the borderline
hypertriglyceridemia group, and 25% and 20% in the
hypertriglyceridemia group, respectively. Overall, the
risks of CVDs and all-cause death were increased by
13% and 12% per 1-mmol/L increase in TG level.
These findings were robust. We incorporated a large
number of participants and deaths (a total of 17,018 CVDs
deaths in 726,030 participants and 58,419 all-cause deaths
in 330,566 participants), which improved the statistical
power for detecting potential associations. Additionally,
the studies included in our sample were carried out world-
wide, with participants from the America, Europe, Asia,
and Australia, thus enhancing generalizability. Further-
more, only prospective cohort studies were considered.
The participants in 33 of the studies had no history of
CVDs at baseline and the follow-up duration in 44 was
more than 10 years, largely eliminating the possibility of
reverse causation relationship. Participants were also se-
lected from the general population, thus reducing potential
selection bias. In addition, we used the Newcastle-Ottawa
Scale to evaluate the quality of studies and most of the
studies (50 studies) included in this meta-analysis were
high-quality (score >6, full score = 9). Finally, there was a
large degree of consistency between the continuous and
categorical analyses.
We observed that elevated TG levels were associated
with an increased risk of CVDs mortality echoing the
findings of several other meta-analyses of prospective
studies demonstrating a relationship between higher TG
levels and an increased risk of cardiovascular events
[4,5,23]. In 1996, Hokanson et al. [4] performed a meta-
analysis comprising 46,413 men and 10,864 women from
the USA and Europe. Their summary crude RRs for fatal
Table 3 Pooled relative risks of all-cause mortality for categorical and continuous analyses in subgroups
Sub-groups Triglyceride group (mg/dl) Per 1 mmol/L TG
<90 90-146 150-199 ≥200
N* RR (95% CI) N* RR† N* RR (95% CI) N* RR (95% CI) N* RR (95% CI)
Age (year)
<50 3 0.88 (0.78, 1.00) 5 1.00 5 1.14 (1.05, 1.24) 5 1.20 (0.99, 1.46) 8 1.13 (1.05, 1.21)
≥50 9 0.97 (0.85, 1.11) 9 1.00 9 1.07 (0.97, 1.18) 3 1.20 (0.97, 1.48) 14 1.12 (1.07, 1.17)
P value 0.311 0.329 0.982 0.845
Gender
Male 8 0.95 (0.84, 1.09) 9 1 9 1.12 (1.02, 1.22) 5 1.23 (1.09, 1.38) 14 1.09 (1.04, 1.13)
Female 6 0.91 (0.84, 0.99) 6 1 6 1.17 (0.99, 1.39) 2 1.01 (0.59, 1.74) 10 1.24 (1.15, 1.32)
Mixed 3 1.00 (0.85, 1.17) 4 1 4 1.11 (1.01, 1.21) 3 1.17 (1.01, 1.35) 6 1.08 (1.03, 1.13)
P value 0.577 0.621 0.491 0.001
Follow-up (year)
<15 6 0.89 (0.84, 0.94) 7 1.00 7 1.11 (0.97, 1.26) 4 1.26 (1.06, 1.51) 14 1.05 (1.02, 1.07)
≥15 6 0.94 (0.79, 1.11) 7 1.00 7 1.09 (1.02, 1.16) 4 1.15 (0.93, 1.41) 8 1.22 (1.16, 1.29)
P value 0.569 0.773 0.490 0.000
Fast status
Fast 8 1.01 (0.86, 1.20) 11 1.00 11 1.08 (0.98, 1.18) 5 1.27 (1.09, 1.48) 15 1.12 (1.06, 1.19)
Nonfast 2 0.91 (0.86, 0.98) 3 1.00 3 1.14 (1.04, 1.24) 3 1.11 (0.88, 1.40) 6 1.11 (1.03, 1.19)
Others§ 2 0.79 (0.63, 0.99) 2 1.00 2 1.11 (0.89, 1.38) 0 - 1 1.19 (1.09, 1.30)
P value 0.258 0.381 0.335 0.740
Geographic location
Europe/America 10 0.96 (0.87, 1.06) 11 1.00 11 1.09 (1.00,1.19) 6 1.19 (0.98, 1.45) 16 1.12 (1.06, 1.17)
Asia-Pacific 2 0.81 (0.59, 1.11) 3 1.00 3 1.12 (1.02, 1.23) 2 1.22 (1.08, 1.39) 6 1.13 (1.08, 1.20)
P value 0.302 0.633 0.813 0.640
Quality score
<7 5 0.90 (0.86, 0.94) 7 1.00 7 1.15 (1.08, 1.24) 4 1.22 (1.07, 1.40) 10 1.13 (1.08, 1.18)
7-9 7 0.95 (0.77, 1.17) 7 1.00 7 1.03 (0.91, 1.17) 4 1.19 (0.91, 1.57) 12 1.11 (1.05, 1.18)
P value 0.594 0.116 0.869 0.707
Sample size
<4000 7 0.97 (0.75, 1.25) 7 1.00 7 1.03 (0.92, 1.15) 4 1.22 (1.03, 1.45) 13 1.14 (1.07, 1.22)
≥4000 5 0.92 (0.86, 0.96) 7 1.00 7 1.14 (1.04, 1.24) 4 1.18 (0.95, 1.45) 9 1.09 (1.04, 1.14)
P value 0.729 0.155 0.778 0.190
Free of CVDs at baseline
Yes 5 0.94 (0.85, 1.03) 6 1.00 6 1.07 (0.99, 1.16) 5 1.24 (0.99, 1.56) 13 1.10 (1.04, 1.16)
No 7 0.97 (0.80, 1.16) 8 1.00 8 1.10 (0.99, 1.23) 3 1.14 (1.00, 1.30) 9 1.13 (1.07, 1.20)
P value 0.711 0.663 0.519 0.480
Adjustment
Minimally 9 0.86 (0.72, 1.03) 10 1.00 10 1.14 (0.99, 1.30) 7 1.38 (1.13, 1.67) 8 1.12 (1.01, 1.24)
Maximally 9 0.94 (0.80, 1.11) 10 1.00 10 1.07 (0.99, 1.17) 7 1.18 (1.01, 1.38) 8 1.07 (1.01, 1.13)
P value 0.466 0.487 0.222 0.432
Adjustment for TC
Yes 5 0.84 (0.7, 0.99) 5 1.00 5 1.03 (0.93, 1.14) 2 1.10 (0.88, 1.38) 11 1.10 (1.05, 1.15)
No 7 1.00 (0.89, 1.12) 9 1.00 9 1.12 (1.02, 1.24) 8 1.27 (1.16, 1.40) 11 1.14 (1.07, 1.21)
P value 0.103 0.225 0.239 0.382
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Table 3 Pooled relative risks of all-cause mortality for categorical and continuous analyses in subgroups (Continued)
Adjustment for HDL
Yes 2 1.03 (0.93, 1.14) 2 1.00 2 1.02 (0.89, 1.17) 1 1.35 (1.09, 1.66) 4 1.07 (1.04, 1.11)
No 10 0.92 (0.82, 1.02) 12 1.00 12 1.11 (1.03, 1.20) 8 1.14 (0.93, 1.39) 18 1.12 (1.07, 1.17)
P value 0.115 0.296 0.250 0.132
*The number of cohorts.
†Reference group.
§Others included mixed and unknown ones.
RR, relative risk; CI, confidence interval; CVDs: cardiovascular diseases; HDL: high-density lipoprotein.
TG: triglycerides; TC: total cholesterol.
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http://www.lipidworld.com/content/12/1/159CVDs from seven prospective studies were 1.24 in men
and 1.84 in women per a 1-mmol/L increase. In the
present meta-analysis, the RRs of CVDs mortality was
lower. However, the discrepancy was unlikely to be
caused by geographic variations as we observed similar
results in the European and American and Asia-Pacific
samples in the present study. Hypertriglyceridemia is
commonly associated with diabetes, obesity, hyperten-
sion, and smoking, which are independent risk factors
for CHD [24,25]. The pooled crude RR in the study by
Hokanson et al. might be confounded by these factors as
the adjusted overall RR of fatal and non-fatal CVDs for
women declined from the crude value of 1.76 to 1.37 [4].
The subgroup analysis of the seven studies that reported
both maximally and minimally adjusted data demon-
strated that the overall RRs were significantly lower for
the maximally adjusted original data, than that for the
minimally adjusted. In the present meta-analysis, the data
in the majority of the studies were adjusted for common
potential confounders, such as age, gender, blood pressure,
BMI, diabetes, smoking and TC, and would thus have bet-
ter validity than unadjusted data.
We also found that an association between elevated TG
levels and an increased risk of all-cause mortality. In fact,
TG levels were found to have a similar predictive power
for CVDs and all-cause mortality. It was thus reasonable
to hypothesize that there was a positive relationship be-
tween TG and non-CVDs death. Prospective studies have
found that elevated TG levels increases the risk of non-
CVDs mortality [26]. A collaborative study of metabolic
syndrome and cancer (Me-Can) involving 514,097 partici-
pants with a 13.4-year follow-up, demonstrated a positive
association between serum TG and risk of cancer overall
and at several sites. The RR (95% CI) for the top quintile
versus the bottom quintile of triglycerides for overall can-
cer was 1.16 (1.06 to 1.26) in men and 1.15 (1.05 to 1.27)
in women [3]. Previous studies have also reported that ele-
vated TG levels increased the risks of other deaths, such
as from kidney disease [27,28] or suicide [29]. Hence,
non-CVDs mortality may contribute to the relative risk of
all-cause mortality.
There are several possible explanations for these find-
ings. Firstly, TG is associated with atherogenic remnantparticles, which have a high uptake into macrophages
leading to foam cell formation. Furthermore, triglyceride-
rich lipoproteins and their remnants promote inflamma-
tion and increase the expression of coagulation factors or
leukocyte adhesion molecules [2]. An increased number of
atherogenic particles may thus adversely influence CVDs
risk. Secondly, hypertriglyceridemia is associated with the
development of oxidative stress and reactive oxygen spe-
cies (ROS) [30]. ROS directly influences cell proliferation
and apoptosis and modulates DNA methylation patterns;
and thus may contribute to the multistage carcinogenesis
process [31]. Additionally, increased oxidative stress in fat
has been shown to be an important pathogenic pathway in
metabolic syndrome. In addition, elevated triglyceride-rich
lipoproteins may adversely influence the risk of chronic
kidney diseases, as triglyceride-rich apolipoprotein B-
containing lipoproteins promote the progression of renal
insufficiency [32]. Moreover, oxidative stress and endothe-
lial dysfunction may cause atherosclerosis-related kidney
damage in older people [33]. Finally, hypertriglyceridemia
has been associated with increased cortisol levels in re-
sponse to stress and symptoms of depression, which may
lead to an increased risk of suicide [29].
In the present study, we found that elevated blood TG
was associated with greater total death and CVDs death
risk in women than in men, which was consistent with
prior studies [4,5]. A collaborative study and a large pro-
spective study also showed that TC and HDL-c were
more predictive of CVDs mortality in women than in
men [34,35]. However, the mechanism remains unclear
and further studies are needed to clarify this issue. The
subgroup analysis in the present study showed that stud-
ies with longer follow-up periods had significantly higher
risk estimates for mortality, possibly due to the greater
cumulative risks associated with longer TG exposure.
This meta-analysis has several limitations. First, there
was considerable heterogeneity among the studies included
with analysis showing that the major sources of heterogen-
eity to be gender, adjustment for TC, and follow-up dur-
ation. Second, 28 studies that included participants with a
prior history of CVDs at baseline were not excluded. Previ-
ous studies have reported that excluding participants with
a history of CVDs at baseline did not substantially change
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http://www.lipidworld.com/content/12/1/159the risks of CVDs mortality [36]. In addition, subgroup
analysis suggested that the overall RRs for all-cause and
CVDs mortality in relation to TG were not markedly influ-
enced by prior CVDs history. Third, elevated TG levels
were accompanied by low HDL-c and high TC, both of
which have been associated with a higher CVDs risk [1,2].
In the present meta-analysis, subgroup analysis observed
that the effect sizes were significantly decreased after ad-
justment for TC although the positive relationship remains
significant. The overall effect estimates were unlikely to be
biased by TC since most of original studies (45/61) re-
ported TC-adjusted RRs, but it tended to be overestimated
because few (10/61) studies reported HDL-adjusted RRs.
Fourth, the studies included in the present meta-analysis
were mainly based on a one-time measurement of baseline
blood TG (five studies adjusted for regression dilution
bias), which may underestimate the associations due to re-
gression dilution effects. Finally, the relatively small num-
ber of studies that included categorical analysis limited the
ability to detect heterogeneity in the subgroup analysis.
In conclusion, elevated blood TG levels were dose-
dependently associated with a greater risk of both CVDs
and all-cause mortality. The findings of this meta-
analysis suggest that controlling TG can help to prevent
CVDs and other causes of death.
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